Adaptive bolus calculators for people with type 1 diabetes: A systematic review
Unsworth R, Avari P, Lett AM, et al.
Diabetes Obes Metab. Pub. online 24 Jul 2023.
Leggi
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
Neves JS, Borges-Canha M, Vasques-Nóvoa F, et al.
J Am Coll Cardiol. 2023;82 (6) 517–525.
Leggi
Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes
Park S, Jeong HE, Bea S, et al.
Diabetes Obes Metab. Pub. online 28 Jul 2023.
Leggi
Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
Balasubramanian P, Kernan WN, Sheth KN, et al.
Stroke. 2023;54(8):2013-2021.
Leggi
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records
Xie Y, Bowe B, Xian H, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(23)00171-7.
Leggi
Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists
Alhiary R, Kesselheim AS, Gabriele S, et al.
JAMA. Pub. online 28 Jul 2023.
Leggi
Nuovi Annali AMD 2022
Carissimi Soci, siamo lieti di condividere i nuovi volumi Annali AMD 2022 – “Valutazione degli indicatori AMD di qualità dell’assistenza al diabete in Italia” - “Diabete tipo 1” e ” Diabete tipo 2”. Siamo giunti alla 12ma edizione di questa iniziativa AMD che ha precorso i tempi in diabetologia contribuendo…
Leggi
